Blood Cancer Drugs Global Market Report 2022 by The Business Research Company is the most comprehensive report available on the market, being wide-ranging both in terms of chronology and geography. It covers the historic period – 2016-2021, and the forecast period – 2022-2026, with additional forecasts for 2026-2031. The report helps gain a truly global perspective as it covers 60 geographies, focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
TBRC’s market report includes a chapter on
the COVID-19 impact on the blood cancer drugs industry, which gives valuable
insights on supply chain disruptions, logistical challenges, and other economic
implications of the virus on the market and how companies can strategize to
bounce back from it. With updated market numbers according to the effects of
the coronavirus, the report provides the most accurate expected blood cancer
drugs market growth numbers from 2022-2031.
Request
a Sample of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp
The global blood cancer drugs market is
expected to grow from $54.83 billion in 2021 to $61.26 billion in 2022 at a
compound annual growth rate (CAGR) of 11.7%. The growth in the market is mainly
due to the companies rearranging their operations and recovering from the
COVID-19 impact, which had earlier led to restrictive containment measures
involving social distancing, remote working, and the closure of commercial
activities that resulted in operational challenges. The global blood cancer
drug market share is expected to reach $89.75 billion in 2026 at a CAGR of
10.0%.
View more on the report:
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
The Blood Cancer
Drugs Global Market Report 2022-31 by The Business Research Company evaluates blood
cancer drugs market size, growth rate, drivers, blood cancer drugs industry
trends, and major companies.
The blood
cancer drugs market segments in the report are:
1) By Blood
Cancer Type: Leukemia, Lymphoma
2) By Drug:
Rituxan/Mabthera (Rituximab), Gleevec/Glivec (Imatinib), Revlimid
(Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst
(Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris
(Brentuximab Vedotin), Others
3) By Treatment
Approach: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies,
Immunotherapeutic
The table of contents in TBRC’s blood cancer drugs market report
includes:
1. Executive Summary
2. Blood Cancer Drugs Market
Characteristics
3. Blood Cancer Drugs Market Trends And
Strategies
4. Impact Of COVID-19 On Blood Cancer Drugs
5. Blood Cancer Drugs Market Size And
Growth
...
27. Blood Cancer Drugs Market Competitive
Landscape And Company Profiles
28. Blood Cancer Drugs Pipeline Analysis
29. Key Mergers And Acquisitions In The
Blood Cancer Drugs Market
30. Blood Cancer Drugs Market Future
Outlook and Potential Analysis
31. Appendix
About The Business Research Company:
The Business
Research Company is a market intelligence firm that excels in company, market,
and consumer research. Located globally it has specialist consultants in a wide
range of industries including manufacturing, healthcare, financial services,
chemicals, and technology. It has offices in the UK, the US and India and
a network of trained researchers in 20+ countries globally.
Get a quick glimpse of our services here: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
No comments:
Post a Comment